{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:23:57Z","timestamp":1777764237001,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P50 DA 06634"],"award-info":[{"award-number":["P50 DA 06634"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.pbb.2021.173217","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T11:36:34Z","timestamp":1623152194000},"page":"173217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chronic levetiracetam (Keppra\u00ae) treatment increases the reinforcing strength of cocaine in rhesus monkeys"],"prefix":"10.1016","volume":"207","author":[{"given":"Paul W.","family":"Czoty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cormac A.","family":"O'Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2021.173217_bb0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque","volume":"485","author":"Bezard","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173217_bb0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1176\/appi.ajp.2009.08121811","article-title":"Randomized, double-blind, placebo-controlled trial of vigabitrin for the treatment of cocaine dependence in Mexican parolees","volume":"166","author":"Brodie","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173217_bb0015","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Kansagara. Pharmacotherapy for cocaine use disorder: a systematic review and meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.pbb.2021.173217_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.001","article-title":"The role of human drug self-administraiton procedures in the development of medicaitons","volume":"96","author":"Comer","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2021.173217_bb0025","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1523\/JNEUROSCI.2699-05.2006","article-title":"Synaptic vesicle protein 2 enhances release probability at quiescent synapses","volume":"26","author":"Custer","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2021.173217_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2006.04.009","article-title":"Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in rhesus monkeys","volume":"85","author":"Czoty","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2021.173217_bb0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-010-1807-x","article-title":"Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys","volume":"209","author":"Czoty","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173217_bb0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/npp.2010.185","article-title":"Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine treatment in rhesus monkeys","volume":"36","author":"Czoty","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pbb.2021.173217_bb0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \u201cpipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2021.173217_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1527-3458.2007.00004.x","article-title":"Levetiracetam: the profile of a novel anticonvulsant drug \u2013 part 1: preclinical data","volume":"13","author":"de Smedt","year":"1997","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.pbb.2021.173217_bb0055","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0269881109359095","article-title":"Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid","volume":"25","author":"Feltner","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2021.173217_bb0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","article-title":"Controversies in translational research: drug self-administration","volume":"199","author":"Haney","year":"2008","journal-title":"Psytchopharmacology"},{"key":"10.1016\/j.pbb.2021.173217_bb0065","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/sj.npp.1300999","article-title":"Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers","volume":"31","author":"Haney","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pbb.2021.173217_bb0070","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2009.11.002","article-title":"New horizons for therapeutics in drug and alcohol abuse","volume":"125","author":"Jupp","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2021.173217_bb0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2 a protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski","year":"2008","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pbb.2021.173217_bb0080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.drugalcdep.2004.03.008","article-title":"A pilot trial of topiramate for the treatment of cocaine dependence","volume":"75","author":"Kampman","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2021.173217_bb0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-3565(24)34966-3","article-title":"The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats","volume":"290","author":"Kushner","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173217_bb0090","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.pbb.2021.173217_bb0095","first-page":"375","article-title":"Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures","volume":"285","author":"Mello","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173217_bb0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.pnpbp.2007.11.023","article-title":"High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam","volume":"32","author":"Pollack","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173217_bb9000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","volume":"66","author":"Richardson","year":"2006","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.pbb.2021.173217_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.physbeh.2005.06.017","article-title":"Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction","volume":"86","author":"Roberts","year":"2005","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2021.173217_bb0110","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2013.30","article-title":"Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57\/BL\/6J mice","volume":"38","author":"Robinson","year":"2013","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pbb.2021.173217_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1535-7511.2009.01351.x","article-title":"SV2A in epilepsy: the plot thickens","volume":"10","author":"Sills","year":"2010","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.pbb.2021.173217_bb0120","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1528-1167.2010.02544.x","article-title":"Alterations of intracerebral gamma-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies","volume":"51","author":"Thorsten","year":"2010","journal-title":"Epilepsia."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721001167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721001167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:00:19Z","timestamp":1777474819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305721001167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":25,"alternative-id":["S0091305721001167"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173217","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic levetiracetam (Keppra\u00ae) treatment increases the reinforcing strength of cocaine in rhesus monkeys","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173217"}}